About 7 results found for searched term "97-39-2" (0.126 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1643 | AEE788 | EGFR/HER2 |
| NVP-AEE 788 | ||
| AEE788 (NVP-AEE788) is a novel multitargeted HER 1/2 and VEGFR 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1. | ||
| M10723 | Ditolylguanidine | Sigma Receptor |
| 1,3-Di-o-tolylguanidine | ||
| Ditolylguanidine (1,3-Di-o-tolylguanidine) is a sigma receptor (σ1/σ2 receptor) agonist. | ||
| M20630 | ex229 (compound 991) | AMPK |
| EX229 (compound 991) is a potent AMPK activator that is 5-10-fold more potent than A769662 in activating AMPK. | ||
| M39844 | Aristolactam A IIIa | DYRK |
| Aristolactam A IIIa (Sch 546909) is a DYRK1A Inhibitor. Aristolactam A IIIa inhibits platelet aggregation induced by arachidonic acid (AA), collagen and platelet-activating factor (PAF). Aristolactam A IIIa has strong cytotoxic effect on HeLa cells. | ||
| M11287 | JNJ-39758979 | Histamine Receptor |
| Jnj-39758979 is a selective, orally active, high-affinity histamine H4 receptor antagonist with Ki values of 12.5, 5.3 and 25 nM for human, mouse and monkey histamine H4 receptor, respectively. Jnj-39758979 antagonized histamine-induced cAMP inhibition with a pA2 of 7.9. Jnj-39758979 has good anti-inflammatory and antipruritic effects. | ||
| M20730 | KGA-2727 | SGLT |
| KGA-2727 is a potent, selective, high-affinity inhibitor of sodium glucose cotransporter 1 (SGLT1) with Ki of 97.4 nM and 43.5 nM for human SGLT1 and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 exhibits antidiabetic efficacy in rodent models. | ||
| M42124 | JNK3 inhibitor-7 | JNK |
| JNK3 inhibitor-7 is a potent, orally active and cross the blood-brain barrier JNK3 inhibitor with IC50 values of 53, 973, 1039 nM for JNK3, JNK2, JNK1, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
